Literature DB >> 23702276

Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids.

Wanling Liang1, Philip C L Kwok2, Michael Y T Chow1, Patricia Tang3, A James Mason4, Hak-Kim Chan3, Jenny K W Lam5.   

Abstract

Nucleic acids have the potential to be used as therapies or vaccines for many different types of disease, but delivery remains the most significant challenge to their clinical adoption. pH responsive peptides containing either histidine or derivatives of 2,3-diaminopropionic acid (Dap) can mediate effective DNA transfection in lung epithelial cells with the latter remaining effective even in the presence of lung surfactant containing bronchoalveolar lavage fluid (BALF), making this class of peptides attractive candidates for delivering nucleic acids to lung tissues. To further assess the suitability of pH responsive peptides for pulmonary delivery by inhalation, dry powder formulations of pH responsive peptides and plasmid DNA, with mannitol as carrier, were produced by either spray drying (SD) or spray freeze drying (SFD). The properties of the two types of powders were characterised and compared using scanning electron microscopy (SEM), next generation impactor (NGI), gel retardation and in vitro transfection via a twin stage impinger (TSI) following aerosolisation by a dry powder inhaler (Osmohaler™). Although the aerodynamic performance and transfection efficacy of both powders were good, the overall performance revealed SD powders to have a number of advantages over SFD powders and are the more effective formulation with potential for efficient nucleic acid delivery through inhalation.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gene delivery; Non-viral vector; Peptides; Pulmonary delivery; Spray drying; Spray freeze drying; pH responsive

Mesh:

Substances:

Year:  2013        PMID: 23702276      PMCID: PMC3948054          DOI: 10.1016/j.ejpb.2013.05.006

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  54 in total

1.  Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.

Authors:  Brigitte Stark; Fritz Andreae; Wilhelm Mosgoeller; Michael Edetsberger; Erwin Gaubitzer; Gottfried Koehler; Ruth Prassl
Journal:  Eur J Pharm Biopharm       Date:  2008-04-27       Impact factor: 5.571

2.  Inhalable lactose-based dry powder formulations of low molecular weight heparin.

Authors:  Shuhua Bai; Vivek Gupta; Fakhrul Ahsan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

3.  Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier.

Authors:  Christopher I Grainger; Leona L Greenwell; David J Lockley; Gary P Martin; Ben Forbes
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

4.  Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA.

Authors:  Ditte Krohn Jensen; Linda Boye Jensen; Saeid Koocheki; Lasse Bengtson; Dongmei Cun; Hanne Mørck Nielsen; Camilla Foged
Journal:  J Control Release       Date:  2011-08-12       Impact factor: 9.776

Review 5.  Gene therapy for chronic obstructive pulmonary disease: twilight or triumph?

Authors:  R Al-Jamal; W A H Wallace; D J Harrison
Journal:  Expert Opin Biol Ther       Date:  2005-03       Impact factor: 4.388

6.  Design and evaluation of histidine-rich amphipathic peptides for siRNA delivery.

Authors:  Bérangère Langlet-Bertin; Christian Leborgne; Daniel Scherman; Burkhard Bechinger; A James Mason; Antoine Kichler
Journal:  Pharm Res       Date:  2010-07       Impact factor: 4.200

7.  Reconstitutable charged polymeric (PLGA)(2)-b-PEI micelles for gene therapeutics delivery.

Authors:  Deepa Mishra; Han Chang Kang; You Han Bae
Journal:  Biomaterials       Date:  2011-02-26       Impact factor: 12.479

Review 8.  Caveolae--an alternative endocytotic pathway for targeted drug delivery.

Authors:  Gyorgy Bathori; Laszlo Cervenak; Istvan Karadi
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2004       Impact factor: 4.889

9.  CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.

Authors:  Liqun Zhang; Brian Button; Sherif E Gabriel; Susan Burkett; Yu Yan; Mario H Skiadopoulos; Yan Li Dang; Leatrice N Vogel; Tristan McKay; April Mengos; Richard C Boucher; Peter L Collins; Raymond J Pickles
Journal:  PLoS Biol       Date:  2009-07-21       Impact factor: 8.029

10.  AON-mediated Exon Skipping Restores Ciliation in Fibroblasts Harboring the Common Leber Congenital Amaurosis CEP290 Mutation.

Authors:  Xavier Gerard; Isabelle Perrault; Sylvain Hanein; Eduardo Silva; Karine Bigot; Sabine Defoort-Delhemmes; Marlèene Rio; Arnold Munnich; Daniel Scherman; Josseline Kaplan; Antoine Kichler; Jean-Michel Rozet
Journal:  Mol Ther Nucleic Acids       Date:  2012-06-26       Impact factor: 10.183

View more
  7 in total

1.  Spray freeze drying of small nucleic acids as inhaled powder for pulmonary delivery.

Authors:  Wanling Liang; Alan Y L Chan; Michael Y T Chow; Fiona F K Lo; Yingshan Qiu; Philip C L Kwok; Jenny K W Lam
Journal:  Asian J Pharm Sci       Date:  2017-10-20       Impact factor: 6.598

2.  Development of a Spray-Dried Formulation of Peptide-DNA Nanoparticles into a Dry Powder for Pulmonary Delivery Using Factorial Design.

Authors:  Miftakul Munir; Vicky L Kett; Nicholas J Dunne; Helen O McCarthy
Journal:  Pharm Res       Date:  2022-04-19       Impact factor: 4.580

Review 3.  Spray-Dried Inhalable Powder Formulations of Therapeutic Proteins and Peptides.

Authors:  Basanth Babu Eedara; Wafaa Alabsi; David Encinas-Basurto; Robin Polt; Heidi M Mansour
Journal:  AAPS PharmSciTech       Date:  2021-06-18       Impact factor: 4.026

4.  Development of Biodegradable Polycation-Based Inhalable Dry Gene Powders by Spray Freeze Drying.

Authors:  Tomoyuki Okuda; Yumiko Suzuki; Yuko Kobayashi; Takehiko Ishii; Satoshi Uchida; Keiji Itaka; Kazunori Kataoka; Hirokazu Okamoto
Journal:  Pharmaceutics       Date:  2015-08-26       Impact factor: 6.321

5.  Manipulating the pH response of 2,3-diaminopropionic acid rich peptides to mediate highly effective gene silencing with low-toxicity.

Authors:  Vincenzo Abbate; Wanling Liang; Jayneil Patel; Yun Lan; Luigi Capriotti; Valentina Iacobucci; Tam T Bui; Poulami Chaudhuri; Laila Kudsiova; Louic S Vermeer; Patrick F L Chan; Xiaole Kong; Alex F Drake; Jenny K W Lam; Sukhvinder S Bansal; A James Mason
Journal:  J Control Release       Date:  2013-10-18       Impact factor: 9.776

Review 6.  Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms.

Authors:  Mark P Murphy; Emma Caraher
Journal:  Drugs R D       Date:  2016-03

Review 7.  Inhalation delivery technology for genome-editing of respiratory diseases.

Authors:  Michael Y T Chow; Rachel Yoon Kyung Chang; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2020-06-05       Impact factor: 15.470

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.